 November 23, 2020 Breda, the Netherlands Ghent, Belgium argenx Euronext Nasdaq: ARGX, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the company has agreed to acquire a U.S. Food and Drug Administration FDA Priority Review Voucher PRV from Bayer Healthcare Pharmaceuticals, Inc for 98 million. A PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application BLA, which reduces the target review time and may potentially lead to an expedited approval. 